BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Endometrial cancer clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for endometrial cancer: 191 (129 sponsors; 23 newly posted in the last 180 days, 10 stopped in the last 180 days; 13 new-entrant sponsors). Momentum score 10.2, rank 67 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 2, Phase 1 66, Phase 2 79, Phase 3 23, Phase 4 2, N/A 19.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| AstraZeneca AZN | 15 | P2 6, NA 4, P3 4, P1 1 | 0 | 1 |
| Merck Sharp & Dohme LLC MRK | 6 | P3 4, P2 1, P1 1 | 1 | 2 |
| GlaxoSmithKline | 10 | P2 4, P4 2, P1 1, P3 3 | 3 | 2 |
| Daiichi Sankyo | 3 | P3 1, P2 2 | 0 | 0 |
| BioNTech SE BNTX | 2 | P2 1, P3 1 | 0 | 0 |
| Evergreen Therapeutics, Inc. | 2 | P2 1, P3 1 | 0 | 1 |
| Genmab GMAB | 2 | P2 1, P3 1 | 0 | 0 |
| Gilead Sciences GILD | 2 | P3 1, P2 1 | 1 | 0 |
| Tesaro, Inc. | 2 | P1 1, P3 1 | 0 | 1 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Hutchmed HCM | 1 | P3 1 | 0 | 0 |
| Kartos Therapeutics, Inc. | 1 | P3 1 | 0 | 0 |
| Karyopharm Therapeutics Inc KPTIQ | 1 | P3 1 | 0 | 0 |
| Pfizer PFE | 1 | P3 1 | 0 | 0 |
| Shanghai Huaota Biopharmaceutical Co., Ltd. new entrant | 1 | P3 1 | 1 | 0 |
| Eli Lilly and Company LLY | 8 | P1 6, P2 2 | 1 | 1 |
| Radiopharm Theranostics, Ltd RADX | 3 | P1 1, EARLY_P1 1, P2 1 | 0 | 0 |
| Advenchen Pharmaceuticals, LLC. new entrant | 2 | P2 2 | 2 | 0 |
| Convalife (Shanghai) Co., Ltd. | 2 | P2 2 | 0 | 0 |
| Eisai Inc. | 2 | P2 2 | 0 | 1 |
| Elephas | 2 | NA 2 | 0 | 1 |
| Ensem Therapeutics | 2 | P2 2 | 1 | 0 |
| GV20 Therapeutics | 2 | P2 2 | 0 | 1 |
| IDEAYA Biosciences IDYA | 2 | P1 2 | 0 | 0 |
| LigaChem Biosciences, Inc. | 2 | P2 1, P1 1 | 0 | 1 |
New-entrant sponsors: Shanghai Huaota Biopharmaceutical Co., Ltd., Advenchen Pharmaceuticals, LLC..
Recently stopped trials
- NCT05194735 Alaunos Therapeutics - terminated: Sponsor halted enrollment on 14 Aug 2023 for business reasons after a Board review of funding needs and permanently discontinued TCR-T cell Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
- NCT06171789 Genmab - terminated: Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation PRO1107 in Patients With Advanced Solid Tumors
- NCT05124743 Alaunos Therapeutics - terminated: Screening moved into TCR001-201 under Amendment 4 (IRB approved 20 Jan 2023; implemented February 2023). Previously enrolled participants co HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumor
- NCT06714617 SystImmune Inc. - terminated: The decision is based only on the Sponsor's internal portfolio prioritization and resource management considerations and is not due to the i Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors
- NCT05827614 Boundless Bio, Inc. - terminated: Decision was made to halt the study based on overall clinical experience and market considerations. This decision was not driven by any safe Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With
- NCT05572684 NextCure, Inc. - terminated: Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial. A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Meta
- NCT05180474 Genmab - terminated: The Sponsor has made a strategic decision to stop the development of GEN1047. GEN1047 for Solid Tumors - First in Human (FIH) Trial
- NCT06466187 Seagen, a wholly owned subsidiary of Pfizer - terminated: The trial was terminated for strategic reasons. The decision was not based on any safety concerns A Study of SGN-MesoC2 in Advanced Solid Tumors
- NCT05325866 Amgen - terminated: Sponsor Decision A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
- NCT04458259 Pfizer - terminated: Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-20 est. | P3 | Merck Sharp & Dohme LLC MRK | NCT04634877 Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer | Endometrial Neoplasms | active not recruiting | 990 |
| 2026-12 est. | P2 | 3D Medicines (Sichuan) Co., Ltd. | NCT05112991 Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer | Advanced Endometrial Cancer | recruiting | 108 |
| 2026-12 est. | P2 | Aadi Bioscience, Inc. | NCT05997017 Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer | Endometrial Cancer; Endometrioid Tumor; Cancer; Tumor; Recurrent Endometrial Carcinoma; Endometrioid | recruiting | 29 |
| 2026-12 est. | P1/P2 | 858 Therapeutics, Inc. | NCT06395519 A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | Advanced or Metastatic Solid Tumors; Breast Cancer; Ovarian Cancer; Prostate Cancer; Epithelial Ovar | recruiting | 120 |
| 2026-12-15 est. | P1/P2 | PMV Pharmaceuticals, Inc PMVP | NCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer; Metastatic Solid Tumor; Lung C | recruiting | 300 |
| 2026-12-15 est. | P1/P2 | GV20 Therapeutics | NCT05669430 A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | Solid Tumor, Adult; Refractory Cancer; Endometrial Carcinoma (EC); Squamous Head and Neck Carcinoma; | recruiting | 365 |
| 2026-12-31 est. | P2 | Jazz Pharmaceuticals JAZZ | NCT06695845 A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | Breast Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Cancer; Colorectal Cancer; Endome | recruiting | 200 |
| 2027-01-01 est. | P1/P2 | Second Life Therapeutics | NCT07341737 SL-28 for Advanced Solid Tumours | Head & Neck Cancer; Pancreas Carcinoma; Pancreas Cancer, Metastatic; Lung Adenocarcinoma; Lung Cance | recruiting | 60 |
| 2027-02 est. | P1/P2 | Day One Biopharmaceuticals, Inc. | NCT05377996 A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors | Triple Negative Breast Cancer; Breast Cancer; Endometrial Cancer; Ovarian Cancer; Fallopian Tube Can | recruiting | 360 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-08-25 | P2 | Hoffmann-La Roche | NCT05634499 A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer | Endometrial Cancer | completed | 33 |
| 2026-06-22 est. | P1/P2 | GlaxoSmithKline | NCT06710847 A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Partic | Neoplasms, Colorectal; Solid Tumor; Colon Cancer; Rectal Cancer; Endometrial Cancer | active not recruiting | 14 |
| 2026-06-17 | P1/P2 | Precision Biologics, Inc DTIL | NCT03476681 Study of NEO-201 in Solid Tumors Expansion Cohorts | Non Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Cervical Cancer; Uterine Cancer | active not recruiting | 121 |
| 2026-06-02 | P1/P2 | Sensei Biotherapeutics, Inc. | NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Solid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancrea | completed | 98 |
| 2026-05-29 | P2 | Incyte Corporation INCY | NCT04463771 Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Wh | Endometrial Cancer | completed | 206 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "endometrial cancer"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.